

Results of the Use of Eropen 700 in the Treatment of Patients with Erectile Dysfunction

Azimov Sardorbek Ilkhomovich
Bukhara State Medical Institute

Abstract: This article presents the results of a study conducted in patients with erectile dysfunction of various etiologies. In the study, male patients of different ages who presented with sexual disorders, decreased libido, premature ejaculation, decreased orgasm, and qualitative and quantitative disorders in spermograms of various degrees, did not observe the development of side effects and complications after taking the drug Eropen 700.

Keywords: Erectile dysfunction, impotence, Eropen 700, decreased libido, testosterone.

INTRODUCTION. Erectile dysfunction is used when there is a permanent or temporary (less than three months) inability to have an erection for sexual intercourse or the inability to maintain an erection until the end of sexual intercourse. Equivalent to this term, the term impotence is used. The use of the term impotence has the effect of stigmatizing patients and prevents them from addressing sexuality issues with patients. In impotence patients have decreased sexual desire, orgasm and ejaculation ability, and this does not always occur as a result of diseases called erectile dysfunction. The term erectile dysfunction is used in a broad sense and includes the partial or complete lack of erection for ejaculation. Based on the statistics of the last year, about 30 million men in the United States, and about 90 million men in the whole world suffer from this pathology in varying degrees of severity. The incidence of erectile dysfunction increases with age, and this is not due to the aging of a person, but to the combination of additional comorbidities. One of the main pathogenetic mechanisms of erectile dysfunction is the result of factors leading to vascular endothelial dysfunction, i.e., oxidative stress, disruption of nitric oxide metabolism, and other causes. In recent years, the increase in the number of cardiovascular diseases was considered one of the main contributing factors to the development of erectile dysfunction. In recent years, the increase in the number of these diseases in the whole world and in Uzbekistan, especially in young men, has caused many psychological and social problems. Finding a solution to these problems, further improvement of diagnosis and treatment methods remains an urgent direction that needs to be found today.

Purpose of the study. The aim of the study was to evaluate the results obtained when using the drug Eropen 700 in the treatment of patients with erectile dysfunction.

Materials and methods. The study was conducted on 50 patients from different districts of Bukhara region who applied to the Department of Urology of Bukhara State Medical Institute and Carmen Plus Hospital from January to March 2024 with erectile dysfunction. Clinical and anamnestic data of patients, erectile function index questionnaire, free testosterone in blood, instrumental examination of spermogram results, according to the treatment plan and after taking the drugs, the instrumental and above-mentioned tests were taken again when taking the drugs for one month and for two months. received information about the results.

Research results. In the study, the results obtained when taking Eropen 700 medicine 2 capsules 1 time in the evening 30 minutes after food for 30 days and 60 days were described. Patients initially selected for the study were first stratified by age. Men selected for the study were divided into the following 3 groups according to age dynamics. A total of 50 selected patients received 100% acceptance. In the first group, 15 patients under the age of 30 made up 30% of the total number of patients, in the second group, 15 patients under the age of 40 made up 30%, and in the third group, 20 patients over the age of 40 made up 40% (table 1).

Table № 1.

№	Number of groups	Number of patients	%
1	Patients under 30 years of age	15	30
3	Patients under 40 years of age	15	30
3	Patients older than 40 years	20	40
	General	50	100 %

Next, the amount of free testosterone in the blood of patients of different age groups was determined. At first, the mean values of testosterone hormone by age were given.

Age-dependent indicators of normal free testosterone in men

Table № 2

Young	Indicators
6-13 years old	4,6ПГ/МЛ
13-19 years old	0,18–23,10 ПГ/МЛ
20-54 years old	1,00–28,28 ПГ/МЛ
55 years old	0,70–21,45 ПГ/МЛ

Results of free testosterone and changes in spermatogram at the time of arrival, 30 days and 60 days of taking Eropen drug in patients under 30 years of age.

Table № 3

Medical history	Free tester on arrival	Free testosterone after 30 days	Free testosterone after 60 days	A+B category % indicator in the spermogram at the time of arrival	After 30 days, the percentage of A+B category in the spermogram	After 60 days, the percentage of A+B category in the spermogram
135291	1,8 ng/ml	2,8 ng/ml	3,8 ng/ml	A+B=12%	A+B=22%	A+B=42%
135242	4,2 ng/ml	4,2 ng/ml	4,6 ng/ml	A+B=16%	A+B=25%	A+B=45%
135071	1,6 ng/ml	2,6 ng/ml	2,7 ng/ml	A+B=23%	A+B=25%	A+B=25%
135056 134831	2,5 ng/ml 4,8 ng/ml	3,5 ng/ml 5,8 ng/ml	4,5 ng/ml 6,1 ng/ml	A+B=25% A+B=18%	A+B=25% A+B=22%	A+B=55% A+B=28%
134413	3,8 ng/ml	4,8 ng/ml	4,8 ng/ml	A+B=18%	A+B=22%	A+B=29%
134262	4,2 ng/ml	5,2 ng/ml	5,5 ng/ml	A+B=20%	A+B=25%	A+B=35%

When the free testosterone level in the blood was checked in patients under 30 years of age, it was found that the free testosterone level was at the normal level in all the results. After 30 days of using Eropen 700, almost every patient experienced an increase in free testosterone, with an average increase of 10-20%. An increase in the percentage of spermatozoa of category A and V was observed in the spermogram analysis. An increase of 10-15% was observed when compared with the analysis at the time of admission. When taken for 60 days, it was found that the amount of free testosterone increased by 20-25%. It was found that spermatozoa of category A and V increased by 15-35% in spermogram

analysis. It was found that patients under 40 years of age and over 40 years of age also received positive results when taking Eropen 700. We can see that the amount of free testosterone in the blood increased by an average of 10-15% after 30 days of consumption, and at 60 days, these indicators increased relatively. Relatively positive results were also obtained in the spermogram analysis.

Conclusion. In this study, when examining the patients with the diagnosis of Erectile Dysfunction in terms of age dynamics, it was found that this pathology occurs more often in patients over 40 years old, and the incidence at this age was 40%. Among young people, we can see that these indicators are much higher, that is, patients under 30 years old made up 30%. In the initial examination, it was found that the results of the erectile function index (MIEF-5) questionnaire were low, the amount of free testosterone in the blood was at the lower limit of normal values, and in the spermogram analysis, the activity of category A and V spermatozoa was relatively low. When Eropen 700 was taken for 30 days, especially in patients under 30 years of age, it was found that the amount of free testosterone increased after 30 days, and after 60 days of taking it, the number of spermatozoa of category A and V in the spermogram increased by 15-35%. Patients under 40 years of age and older had a positive effect on questionnaire, free testosterone in blood and spermogram indicators..

REFERENCES

1. Azimov S. I. Current international standards for monitoring lower urinary tract symptoms and signs of benign prostatic hyperplasia and tuberculosis patients. *Journal of Natural Remedies* Vol.22, №.1(2), (2021) pp.117-123
1. Shodiev O'lmas Mustafoevich, Expression level of anti-apoptotic protein Bcl-2 in bladder papillomas(2022/8/13). *Web of Scientist: International Scientific research Journal*. № 3(8) P. 297-305
2. Azimov S. I. Immunological Description of the Study of Urological Diseases Accompanied by Pulmonary Tuberculosis. *Medical and natural sciences*. - 2022 - Volume 03, Issue 04. - P.247-250.
3. Azimov S. I. Immune Dysfunctions and Their Prevention During the Use of the Drug Canefron N in the Complex Treatment of Chronic Pyelonephritis. *European Journal of Modern Medicine and Practice*. - 2022 - Volume 02, Issue 05. - P.54-58.
4. Azimov S. I., Rashidov Z. R. The Role of the Universal Urological Questionnaire in the Screening of Urological Pathology in Patients with Tuberculosis // *American Journal of Medicine and Medical Sciences*, 2020 10(10), pp. 769-772
5. Kapsargin F.P., Volkova G.A., Zukov R.A., Grushkin Yu.V., Pavlovskii S.V., Repina E.V. Analiz obshchedostupnoi reabilitatsii erektil'noi disfunktsii u molodykh muzhchin. *Voprosy diagnostiki i lecheniya urologicheskikh zabolevaniy*. Nauchno-prakticheskaya konferentsiya urologov Zapadnoi Sibiri. 12–13 maya, 2004; Biisk. eLIBRARY ID: 28932354.
6. Salakhaldin R.D. Epidemiologiya erektil'noi disfunktsii: Avtoref. dis. ... kand.med.nauk. Rostov-na-Donu, 2003.
7. Pushkar' D.Yu., Kamalov A.A., Al'-Shukri S.Kh., Erkovich A.A., Kogan M.I., Pavlov V.N., Zhuravlev V.N., Bernikov A.N. Epidemiologicheskoe issledovanie rasprostranennosti erektil'noi disfunktsii v Rossiiskoi Federatsii. *Russkii meditsinskii zhurnal*. 2012;20(3):112-115. eLIBRARY ID: 17826950.
8. Lue T.F. Erectile dysfunction. *The New England Journal of Medicine*. 2000;342(24):1802–1813
9. Gratzke C, Angulo J, Chitale K, Dai YuT, Kim NN, Paick JS, Simonsen U, Uckert S, Wespes E, Andersson KE, Lue TF, Stief CG. Anatomy, physiology, and pathophysiology of erectile dysfunction. *The Journal of Sexual Medicine*. 2010;7(1):445–475.
10. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E, European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. *European Urology*. 2010;57(5):804–814

11. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. *European Urology*. 2005;47(1):80-85